HUMIRA^® Pen: a novel autoinjection device for subcutaneous injection of the fully human monoclonal antibody adalimumab

Abstract

The HUMIRA^® (adalimumab) Pen is a novel, integrated, disposable autoinjection delivery system for the subcutaneous injection of adalimumab. Adalimumab is a biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor. Sustaining long-term efficacy with a biological therapy is influenced by patient adherence to the therapeutic regimen, which is often affected by the route of drug administration. Self-administered injectables offer several advantages over intravenous injections (i.e., portability, convenience and flexible scheduling). In particular, patients with chronic, debilitating diseases may need a self-administered medication available in an easy-to-use and convenient delivery device that minimizes pain and facilitates adherence to therapy. The adalimumab Pen offers these benefits and recent evidence indicates that patients overwhelmingly prefer the adalimumab Pen to the prefilled syringe.

Keywords::

• adalimumab
• ankylosing spondylitis
• autoinjection pen
• patient preference
• prefilled syringe
• psoriatic arthritis
• rheumatoid arthritis
• TNF antagonist